Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
The Journal of Rheumatology|March 19, 2013
Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPTPhilip J Mease, Michele Heckaman, Sonja Kary, et al.
Arthritis Research & Therapy|March 17, 2010
Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritisMartin Rudwaleit, Pascal Claudepierre, Martina Kron, et al.
Arthritis Research & Therapy|June 18, 2010
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapyMartin Rudwaleit, Filip Van den Bosch, Martina Kron, et al.
Rheumatology (Oxford, England)|May 8, 2010
Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasisJürgen Braun, Martin Rudwaleit, Sonja Kary, et al.
Arthritis Care & Research|September 27, 2017
Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III TrialBurkhard Möller, Judith Everts-Graber, Stefan Florentinus, et al.
The Journal of Rheumatology|April 3, 2015
Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestationsFilip Van den Bosch, Arthur Kavanaugh, Martina Kron, et al.
RMD Open|June 30, 2018
Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritisEdward C Keystone, Ferdinand C Breedveld, Hartmut Kupper, et al.
Rheumatology (Oxford, England)|July 23, 2015
Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapyDaniel E Furst, Arthur Kavanaugh, Stefan Florentinus, et al.
Clinical Rheumatology|February 4, 2014
Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 yearsDaniel J Kingsbury, Brigitte Bader-Meunier, Gina Patel, et al.
Clinical and Experimental Rheumatology|April 10, 2019
Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate- or methotrexate-treated rheumatoid arthritis patients in OPTIMAAlla Skapenko, Josef S Smolen, Arthur Kavanaugh, et al.
Pageof 5